A Phase 1 Open Label Study of the Safety and Pharmacokinetics of SM-03, an anti-CD22 antibody, in Chinese Systemic Lupus Erythematosus Subjects With Active Disease

Trial Profile

A Phase 1 Open Label Study of the Safety and Pharmacokinetics of SM-03, an anti-CD22 antibody, in Chinese Systemic Lupus Erythematosus Subjects With Active Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2016

At a glance

  • Drugs SM 03 (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Pharmacokinetics
  • Sponsors SinoMab Bioscience Ltd
  • Most Recent Events

    • 18 Jul 2016 Results published in the Clinical Drug Investigation
    • 21 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top